SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i’s promote a general shift to fasting state metabolism chara...
Main Authors: | Damilola D. Adingupu, Sven O. Göpel, Julia Grönros, Margareta Behrendt, Matus Sotak, Tasso Miliotis, Ulrika Dahlqvist, Li-Ming Gan, Ann-Cathrine Jönsson-Rylander |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0820-6 |
Similar Items
-
Symposium 13: Prediabetes and brain
by: Gustavo Díaz
Published: (2022-09-01) -
Assessment of Chromium Levels in Patients with Prediabetes
by: Zahra Torabi, et al.
Published: (2014-04-01) -
Preferences and Adherence of People with Prediabetes for Disease Management and Treatment: A Systematic Review
by: Ren Z, et al.
Published: (2023-11-01) -
Apnea del sueño en prediabetes y obesidad
by: Daniel Schönfeld
Published: (2023-08-01) -
O1 Early indicators of prediabetes and the appropriate treatment
by: Rocio Torrieri, et al.
Published: (2020-11-01)